| Nov 12 |
Nanobiotix gives Q3 update
|
| Nov 12 |
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
|
| Oct 31 |
NANOBIOTIX to Participate in Multiple Investor Conferences in November
|
| Sep 18 |
Nanobiotix reports 1H results
|
| Sep 18 |
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
|
| Sep 4 |
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
|
| Sep 3 |
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Jun 12 |
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
|
| Jun 11 |
Voting Rights and Shares Capital of the Company
|
| Jun 2 |
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
|
